The impact of COVID-19 on antipsychotic prescriptions for patients with schizophrenia in Australia | Zendy

Steve Kisely | Zendy; Dante Dangelo-Kemp | Zendy; Mark Taylor | Zendy; Dennis Liu | Zendy; Simon Matthew Graham | Zendy; Jodie Hartmann | Zendy; Sam Colman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The impact of COVID-19 on antipsychotic prescriptions for patients with schizophrenia in Australia

Author(s) -

Steve Kisely,

Dante Dangelo-Kemp,

Mark Taylor,

Dennis Liu,

Simon Matthew Graham,

Jodie Hartmann,

Sam Colman

Publication year - 2021

Publication title -

australian and new zealand journal of psychiatry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.66

H-Index - 116

eISSN - 1440-1614

pISSN - 0004-8674

DOI - 10.1177/00048674211025716

Subject(s) - medical prescription , antipsychotic , medicine , schizophrenia (object oriented programming) , pharmaceutical benefits scheme , covid-19 , psychiatry , population , retrospective cohort study , pediatrics , family medicine , environmental health , pharmacology , disease , infectious disease (medical specialty)

To assess the impact, in the Australian setting, of the COVID-19 lockdown on antipsychotic supplies for patients with schizophrenia following a prescription from a new medical consultation when compared to the same periods in the previous 4 years. A secondary objective was to assess the volume of all antipsychotic supplies, from new and repeat prescriptions, over these same periods.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research